Literature DB >> 23010422

Blockade of orexin receptor 1 attenuates the development of morphine tolerance and physical dependence in rats.

Elaheh Erami1, Hassan Azhdari-Zarmehri, Abolfazl Rahmani, Elmira Ghasemi-Dashkhasan, Saeed Semnanian, Abbas Haghparast.   

Abstract

The goals of this study were to evaluate the effects of pretreatment by orexin receptor-1 antagonist on the development of morphine tolerance and physical dependence in rat. Animals were rendered dependent on morphine by subcutaneous (SC) injection of morphine sulfate (10mg/kg) at set intervals of 12h for 10days. Just before the morphine administration, the animals received SB-334867, a selective orexin receptor 1 (OXR1) antagonist. To assess morphine tolerance, the antinociceptive responses of morphine were measured using the warm-water tail immersion test before and after its administration. On day 11, naloxone was injected 2h after morphine administration and the physical dependence evaluated by quantifying/scoring naloxone-precipitated withdrawal signs for 30min. The effect of chronic SB-334867 on locomotion was carried out by calculating the number of grid crossings as a measure of locomotor activity. Our findings demonstrated that although morphine-tolerance tended to develop in response to repeated injections of morphine, pre-treatment of OXR1 antagonist prevented this effect, causing a delay in the development of morphine-tolerance. Moreover, co-administration of orexin receptor 1 antagonist with morphine significantly decreased the somatic signs of withdrawal including diarrhea, teeth chattering, jumping, and defecation. Administration of SB-334867 alone or in a chronic co-administration with morphine failed to change locomotor activity. These results suggest that the activation of OXR1 might be involved in the development of morphine tolerance and dependence.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010422     DOI: 10.1016/j.pbb.2012.08.010

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

1.  Assessment of affective and somatic signs of ethanol withdrawal in C57BL/6J mice using a short-term ethanol treatment.

Authors:  E E Perez; M De Biasi
Journal:  Alcohol       Date:  2015-03-06       Impact factor: 2.405

Review 2.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

3.  Tail flick modification of orexin-a induced changes of electrophysiological parameters in the rostral ventromedial medulla.

Authors:  Hassan Azhdari-Zarmehri; Saeed Semnanian; Yaghoub Fathollahi; Firouz Ghaderi Pakdel
Journal:  Cell J       Date:  2014-05-25       Impact factor: 2.479

4.  Orexin-a modulates firing of rat rostral ventromedial medulla neurons: an in vitro study.

Authors:  Hassan Azhdari-Zarmehri; Saeed Semnanian; Yaghoub Fathollahi
Journal:  Cell J       Date:  2015-04-08       Impact factor: 2.479

5.  Yokukansan (Kampo medicinal formula) prevents the development of morphine tolerance by inhibiting the secretion of orexin A.

Authors:  Ayami Katayama; Yasuaki Kanada; Mana Tsukada; Yuko Akanuma; Haruka Takemura; Takahiro Ono; Hiroki Suga; Hitoshi Mera; Tadashi Hisamitsu; Masataka Sunagawa
Journal:  Integr Med Res       Date:  2018-03-08

6.  Long non-coding RNA MEG3 attends to morphine-mediated autophagy of HT22 cells through modulating ERK pathway.

Authors:  Shuibo Gao; Enyao Li; Haixia Gao
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

Review 7.  Kampo Formulae for the Treatment of Neuropathic Pain ∼ Especially the Mechanism of Action of Yokukansan ∼.

Authors:  Masataka Sunagawa; Yasunori Takayama; Mami Kato; Midori Tanaka; Seiya Fukuoka; Takayuki Okumo; Mana Tsukada; Kojiro Yamaguchi
Journal:  Front Mol Neurosci       Date:  2021-12-14       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.